200 related articles for article (PubMed ID: 9463281)
1. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
[TBL] [Abstract][Full Text] [Related]
2. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
[TBL] [Abstract][Full Text] [Related]
3. [The clinical and flowmetric results of the treatment of benign prostatic hyperplasia with doxazosin].
Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1999 Sep; 52(7):739-48. PubMed ID: 10540764
[TBL] [Abstract][Full Text] [Related]
4. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
6. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
Chung BH; Hong SJ; Lee MS
Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
[TBL] [Abstract][Full Text] [Related]
7. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
[TBL] [Abstract][Full Text] [Related]
8. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
9. Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia.
Zhang Y; Wang Y; Zhang P; Zhang XD; Yang Y
Transplant Proc; 2009 Nov; 41(9):3747-51. PubMed ID: 19917379
[TBL] [Abstract][Full Text] [Related]
10. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung BH; Hong SJ
BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
[TBL] [Abstract][Full Text] [Related]
12. Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
Gerber GS; Contreras BA; Rukstalis DB
Tech Urol; 1997; 3(3):164-7. PubMed ID: 9422449
[TBL] [Abstract][Full Text] [Related]
13. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
Samli MM; Dincel C
Urol Int; 2004; 73(2):125-9. PubMed ID: 15331896
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
15. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
[TBL] [Abstract][Full Text] [Related]
16. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
Roehrborn CG; Prajsner A; Kirby R; Andersen M; Quinn S; Mallen S
Eur Urol; 2005 Sep; 48(3):445-52; discussion 452. PubMed ID: 15996811
[TBL] [Abstract][Full Text] [Related]
17. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction.
Sriplakich S; Promwatcharanon K
J Med Assoc Thai; 2007 Nov; 90(11):2326-31. PubMed ID: 18181315
[TBL] [Abstract][Full Text] [Related]
18. [Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia].
Xiao H; Li HZ; Huang ZM; Li YQ
Zhonghua Wai Ke Za Zhi; 2010 Dec; 48(23):1771-3. PubMed ID: 21211380
[TBL] [Abstract][Full Text] [Related]
19. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
20. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
